At 32.4x earnings and 27.9x forward earnings, the market is pricing BMI as a quality compounder rather than a cyclical instrument name, and the 1.8 forward PEG confirms investors are paying a premium for expected growth. However, a 13.4 Altman Z-Score signals extremely low bankruptcy risk, and a 3.4 current ratio reinforces balance sheet stability. With ROIC at 20.90% and operating margins at 19.90%, this is a capital-efficient operator, but the valuation leaves limited room for execution error. This is not statistically cheap; it is a quality franchise priced for continued precision execution rather than turnaround upside.